A case of CALR mutation in JAK2-negative patient with polycythemia-Reference-Cited by-同舟云学术

A case of CALR mutation in JAK2-negative patient with polycythemia

Published:2022-04-11 Issue:2 Volume:17 Page:30-35
ISSN:2413-4023
Container-title:Oncohematology
language:
Short-container-title:Onkogematologiâ

Author:

Subbotina T. N.¹^ORCID,Maslyukova I. E.²^ORCID,Kurochkin D. V.²^ORCID,Mikhalev M. A.³^ORCID,Osadchaya M. G.⁴^ORCID,Khorzhevskiy V. A.⁵^ORCID,Garkusha T. A.⁵^ORCID,Dunaeva E. A.⁶^ORCID,Mironov K. O.⁶^ORCID

Affiliation:

1. Siberian Federal University; Federal Siberian Research and Clinical Center of the Federal Medical and Biological Agency

2. Siberian Federal University

3. Regional Clinical Hospita

4. Krasnoyarsk Interdistrict Polyclinic No. 1

5. Krasnoyarsk State Regional Bureau of Pathology

6. Central Research Institute of Epidemiology of the Federal Service on Customers’ Rights Protection and Human Well-being Surveillance

Publisher

Publishing House ABV Press

Subject

Oncology,Hematology

Reference15 articles.

1. Tefferi A., Thiele J., Vannucchi A.M., Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014;28(7):1407–13. DOI:10.1038/leu.2014.35.

2. Luo W., Yu Z. Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs). Stem Cell Invest 2015;2:16. DOI:10.3978/j.issn.2306-9759.2015.08.01.

3. Klampfl T., Gisslinger H., Harutyunyan A.S. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369(25):2379–90. DOI:10.1056/NEJMoa1311347.

4. Nangalia J., Massie C.E., Baxter E.J. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369(25):2391–405. DOI:10.1056/NEJMoa1312542.

5. Broseus J., Park J.H., Carillo S. et al. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood 2014;124(26):3964–6. DOI:10.1182/blood-2014-06-583161.